top of page

Incubate Applauds Reauthorization of SBIR and STTR Programs Through 2031

WASHINGTON (April 13) -- Today, President Trump signed into law the Small Business Innovation and Economic Security Act, which reauthorizes the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs through 2031.

 

Incubate Executive Director John Stanford issued the following statement:

 

"The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs are lifelines for early-stage biotech startups. We commend Senators Ed Markey (D-MA) and Joni Ernst (R-IA) for their leadership in introducing this legislation and appreciate Congress for reauthorizing these vital programs after a six-month lapse.

 

Each year, SBIR and STTR provide billions of dollars in competitive funding across thousands of grants, supplying the critical seed capital that allows high-risk, high-reward science to move from the lab toward commercialization. For many emerging biotech companies, SBIR funding is the first meaningful investment that helps validate a technology and attract the private capital that funds further research and ultimately delivers lifesaving new medicines and devices to patients.

 

In recent years, uncertainty surrounding foreign risk reviews has left some NIH applicants in limbo, with little insight into how determinations were made. By requiring greater transparency around these decisions, Congress has taken an important step toward ensuring that small businesses better understand how those determinations are reached.

 

Extending the programs through 2031 provides the long-term certainty that startups and investors need. That stability will help emerging biotech companies plan, raise capital, and advance cutting-edge research over the next half-decade."

 

###

 

About Incubate

Incubate is a 501(c)(4) organization of venture capital firms representing the patient, corporate, and investment communities. Our primary aim is to educate policymakers on the role of venture capital in bringing promising treatments to patients in need.

 

MEDIA CONTACT:

Bridget Brown

(202) 858-2333



 
 
 

Comments

bottom of page